An extensive long-term study has revealed that survivors of breast cancer who regularly took aspirin, after their treatment had successfully been completed, were 50% less likely to die or suffer from tumors which end up spreading around the body, as compared to those survivors who were not on aspirin. The study involved a total of 4,164 nurses.

The study has emerged as the first ever to discover that regular aspirin users had a lower risk of dying from breast cancer, as has been confirmed by the study authors.

Study author Michelle Holmes of Harvard Medical School, and Brigham and Women's Hospital has stressed that aspirin might help control cancer by fighting off inflammation, and breast cancers end up producing more inflammatory chemicals as compared to normal breast cells.

A study carried out in August had also discovered that aspirin ended up offering substantial benefit against colon cancer.

Details of the study have been published in the Journal of Clinical Oncology.